CD8A and invasive breast carcinoma: The authors employed multiplex immunostaining, including CD20(+) B, CD3(+)CD8(+) T, CD3(+)FOXP3(+) regulatory T cells, CD68(+) cells, and CD8(+)Ki67(+) proliferating T cells, and found that the assessment of these markers in the TME was not a predictor of invasive breast carcinoma development [36].